SK&S’ transaction team advised Velocity Clinical Research Inc.—the leading multi-specialty clinical sites business, in the acquisition of KO-MED Clinical Centers—one of the leading clinical trials companies in Poland.
Velocity is the leading integrated site organisation for clinical trials. With over 90 sites and more than 220 investigators, Velocity partners with pharmaceutical and biotechnology companies to research new drugs, medical devices, diagnostics, and combination products.
KO-MED is a network of modern and dynamic clinical trial sites that enroll patients from all over Poland into clinical trials. Their mission is to carry out clinical trials that provide patients with an opportunity to regain health and contribute to the development of medicine. The organization has been running its business for 20 years and has completed hundreds of clinical trials.
The acquisition of KO-MED is Velocity’s first foray into Oncology research, which accounts for roughly 40-50% of clinical trials globally. KO-MED has been the leading multi-site network in Poland since 2020, having enrolled over 9,000 patients into clinical research.
This is yet another transaction concluded with the Velocity. In 2023, our attorneys advised in the acquisition of its first site in Poland—ClinMedica Research in Skierniewice.
Our transaction team advised on all stages of the transaction process, including the due diligence as well as the preparation and negotiation of the transaction documentation.
SK&S’ team was headed by partner Krzysztof Pawlisz and included Karol Skibniewski (Senior Counsel), Anna Bartosiewicz (Senior Associate), Magdalena Rożek (Associate) and Piotr Mordzonek (Associate). The transaction team was supported by Piotr Andrzejak (Partner; tax law), dr. Tomasz Grabka (Senior Associate, tax law), Katarzyna Juralewicz (Associate; tax law), Agnieszka Fedor (Partner; labor law), Jacek Myszko (Partner; life sciences), Ewelina Woike-Reguła (Associate; life sciences) and Natalia Łabęda (Senior Associate; real estate), among others.
The seller was advised by: Osborne Clarke Olkiewicz Świerzewski i Wspólnicy, Factor Consulting oraz MDDP Michalik Dłuska Dziedzic i Partnerzy.
